StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene

HCID 170361
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
249296-44-4
Standard-SMILES
c1cnc2cc3c(cc2n1)C1CNCC3C1
InChIKey
JQSHBVHOMNKWFT-UHFFFAOYSA-N
Summenformel
C13H13N3
Durchschnittliche Molmasse
211,26 g/mol
Monoisotopische Masse
211,11094743

Überblick

Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.

Namen und Bezeichner

Bevorzugter Name
5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene
IUPAC
5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene
Englischer Name
Varenicline
Summenformel
C13H13N3
Molmasse
211.26

Namen und Synonyme

5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaeneAB01568242_01Varenicline (INN)5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2(11),3,5,7,9-pentaeneNCGC00247735-01NCGC00247735-02VareniclinVarenicline?SCHEMBL225687CHEMBL556954orb1690005SCHEMBL29363551
Weitere Namen anzeigen
ChantixVarenciline10-tetrahydro-Varenicline free base7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline(1R,12S)-5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2,4(9),5,7,10-pentaeneCS-861Hsdb 7591Cp 526555VARENICLINE
7,8,9,10-tetCP 526555; Champix; ChantixHMS5087H05BDBM50166908s6985T4246LAKOS005145561CS-0396

Datenbank-Bezeichner

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
0,8
Polarare Oberfläche (TPSA)
37,8 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
0
Schwere Atome
16
Formalladung
0
Komplexität
254

Physikochemische Eigenschaften

Schmelzpunkt
138.5 °C · 138.5 °C
Siedepunkt
400.6 · 400.6±40.0 °C(Predicted)
Dichte
1.247 · 1.247±0.06 g/cm3(Predicted)
storage temp.
-20 °C · Store at -20°C
Löslichkeit
Soluble in DMSO
Aggregatzustand
Powder
pka
9.6 · 9.60±0.20(Predicted)
Farbe
Light yellow to yellow
BCS Class
1 · 1
Stabilität
Hygroscopic
InChI
InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2
InChIKey
JQSHBVHOMNKWFT-UHFFFAOYSA-N
SMILES
N1CC2CC(C3=CC4=NC=CN=C4C=C32)C1

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Sicherheitsdaten

Giftige Stoffe Daten
249296-44-4(Hazardous Substances Data)

Chemie und Industrie

Pharmakologische Informationen

Protein BindingLess than 20%.
PharmacodynamicsVarenicline is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain.
Mechanism of Action · 1 Eintrag

Varenicline is an alpha-4 beta-2 neuronal nicotinic acetylcholine receptor partial agonist. The drug shows high selectivity for this receptor subclass, relative to other nicotinic receptors (>500-fold alpha-3 beta-4, >3500-fold alpha-7, >20,000-fold alpha-1 beta gamma delta) or non-nicotinic receptors and transporters (>2000-fold). The drug competitively inhibits the ability of nicotine to bind to and activate the alpha-4 beta-2 receptor. The drug exerts mild agonistic activity at this site, though at a level much lower than nicotine; it is presumed that this activation eases withdrawal symptoms.

Biological Half-LifeThe elimination half-life of varenicline is approximately 24 hours
Metabolism/MetabolitesMetabolism is limited (<10%). Most of the active compound is excreted by the kidneys (81%). A minor amount of varenicline is glucuronidated, oxidated, N-formylated, as well as conjugated to form a hexose.
Absorption, Distribution and Excretion · 1 Eintrag

Varenicline undergoes minimal metabolism, with 92% excreted unchanged in the urine. Renal elimination of varenicline is primarily through glomerular filtration along with active tubular secretion possibly via the organic cation transporter, OCT2.

Anwendungen · 2 Einträge

BeschreibungVarenicline, a partial agonist of the a4b2 nicotinic receptor, is a first-in-class drug launched by Pfizer as an aid to smoking cessation treatment. Varenicline exhibits dual action by decreasing craving and withdrawal symptoms, and by decreasing the reinforcement associated with smoking. The addictive properties of nicotine are thought to be mediated in part through its action as an agonist at α4β2 neuronal nicotinic acetylcholine receptors (nAChRs). Activation of α4β2 receptors by nicotine increases the release of dopamine in the mesolimbic system, an effect that is shared by most drugs of abuse. As nicotine levels decrease, dopamine levels decline, which in turn stimulates the urge to smoke. Additionally, a reduced dopaminergic tone due to abstinence from smoking stimulates craving and the withdrawal syndrome. A partial agonist of α4β2 receptors such as varenicline is expected to elicit a moderate and sustained increase in dopamine levels to relieve craving and withdrawal symptoms. In addition, by competitively binding to a4b2 receptors and inhibiting nicotineinduced dopaminergic activation, a partial agonist could attenuate the pharmacologic reward associated with smoking.

Zugehörige Reaktionen

12
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 914732
HRID 914732als Produktals Edukt
Reaktionsgleichung von HRID 914733
HRID 914733als Edukt
Reaktionsgleichung von HRID 1665791
HRID 1665791als Edukt
Reaktionsgleichung von HRID 1665792
HRID 1665792als Produkt
Reaktionsgleichung von HRID 1665793
HRID 1665793als Produkt
Reaktionsgleichung von HRID 1665794
HRID 1665794als Produkt
Reaktionsgleichung von HRID 1879292
HRID 1879292als Edukt
Reaktionsgleichung von HRID 2092910
HRID 2092910als Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
CAS
249296-44-4
PubChem CID
170361
DTXSID
DTXSID70891447
Nikkaji
J2.566.151F

VerwendenVarenicline is a useful medication for smoking cessation.

Vor- und nachgelagerte Produkte

Nachgelagerte Produkte

Varenicline tartrate

Ergänzende Hinweise

DefinitionChEBI: An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.